Dropping the BACE: Beta Secretase (BACE1) as an Alzheimer’s Disease Intervention Target

نویسندگان

  • Justin Read
  • Cenk Suphioglu
چکیده

The β-site amyloid precursor protein cleaving enzyme 1 (BACE1) is an important regulator for the production of amyloid plaques, a characteristic of the Alzheimer’s disease (AD) brain. The proteolytic cleavage of the amyloid precursor protein (APP), by BACE1, produces an insoluble amyloid-β (Aβ) fragment which has the ability to aggregate and migrate onto the dendrites and cell body of neuronal cells, initiating chronic immune responses of inflam‐ mation and microglia activation.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Expression analysis of beta-secretase 1 (BACE1) enzyme in peripheral blood of patients with Alzheimer\'s disease

Background: Recent evidence has indicated that beta-secretase 1 (BACE1) is involved in the production of amyloid beta (Aβ) in patients affected with Alzheimer’s disease (AD). Therefore; the purpose of this study was to measure mRNA and plasma levels of BACE1 in AD patients, as an early diagnosis biomarker for such individuals. Methods: A total number of thirty AD patients and thirty normal sub...

متن کامل

Targeting BACE with small inhibitory nucleic acids - a future for Alzheimer's disease therapy?

beta-Secretase, a beta-site amyloid precursor protein (APP) cleaving enzyme (BACE), participates in the secretion of beta-amyloid peptides (Abeta), the major components of the toxic amyloid plaques found in the brains of patients with Alzheimer's disease (AD). According to the amyloid hypothesis, accumulation of Abeta is the primary influence driving AD pathogenesis. Lowering of Abeta secretion...

متن کامل

Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE.

Cerebral deposition of amyloid beta peptide (Abeta) is an early and critical feature of Alzheimer's disease. Abeta generation depends on proteolytic cleavage of the amyloid precursor protein (APP) by two unknown proteases: beta-secretase and gamma-secretase. These proteases are prime therapeutic targets. A transmembrane aspartic protease with all the known characteristics of beta-secretase was ...

متن کامل

Design of Potent and Highly Selective Inhibitors for Human β-Secretase 2 (Memapsin 1), a Target for Type 2 Diabetes.

Design, synthesis and evaluation of very potent and selective β-Secretase 2 (memapsin 1, BACE 2) inhibitors are described. The inhibitors were designed specifically to interact with the S2'-site of β-secretase 2 to provide >170,000-fold selectivity over β-secretase (BACE 1) and >15,000-fold selectivity over cathepsin D. BACE 2 is implicated in Type 2 diabetes. The studies serve as an important ...

متن کامل

The Design, Development, and Evaluation of BACE1 Inhibitors for the Treatment of Alzheimer’s Disease

Alzheimer’s disease (AD) is a very serious public health problem. Currently, there is no effective treatment for AD. Among the many biochemical targets for AD drug development, β-secretase (BACE1, memapsin 2) continues to be a promising drug discovery target for AD therapy. This proteolytic enzyme is a membrane-anchored aspartic acid protease that is responsible for the initial step of amyloid ...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:

دوره   شماره 

صفحات  -

تاریخ انتشار 2013